Does Blue Cross Blue Shield of Illinois Cover Forteo?

What Is Forteo and Why Does Coverage Get Complicated?

Forteo is a brand-name anabolic bone-building agent, not a cheap generic. Teriparatide, its active molecule, is a recombinant 34-amino-acid fragment of human parathyroid hormone. The drug stimulates new bone formation rather than simply slowing resorption, which sets it apart from bisphosphonates like alendronate. That pharmacological distinction also puts it in a completely different cost category.

The FDA approved Forteo in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis (FDA label, NDA 021318). The list price for a 28-day supply pen has historically exceeded $3,000, which is why payers including BCBSIL place it behind multiple coverage gates.

Osteoporosis itself is far from a rare condition. The National Osteoporosis Foundation estimates that roughly 10 million Americans have osteoporosis and another 44 million have low bone density, placing more than half of adults over age 50 at fracture risk (NIH Osteoporosis Overview). BCBSIL, as the largest commercial insurer in Illinois, covers hundreds of thousands of patients who could theoretically qualify for teriparatide. Its utilization management policies for this drug are therefore worth understanding in detail before you submit a prescription.

How BCBSIL Formularies Are Organized and Where Forteo Sits

BCBSIL operates under the Health Care Service Corporation (HCSC) umbrella and uses a tiered formulary system with tiers typically running from Tier 1 (preferred generics) through Tier 4 or Tier 5 (specialty/non-preferred specialty). Forteo lands on Tier 3 or Tier 4 depending on the specific plan product.

Commercial PPO and HMO plans. On BCBSIL's most common commercial formularies, teriparatide appears as a Tier 4 specialty medication. A Tier 4 specialty designation means coinsurance rather than a flat copay, often 20 to 30% of the negotiated drug cost after the deductible is met. Even after meeting a $1,500 individual deductible, a member could owe $600, $900 per monthly pen.

Blue Advantage HMO (marketplace/ACA plans). These plans frequently carry the same Tier 4 placement. The ACA's out-of-pocket maximum cap (set at $9,450 for self-only coverage in 2025) does provide a ceiling, but a patient on Forteo alone could hit that cap quickly.

Medicare Advantage (Blue Cross Medicare Advantage PPO and HMO). Medicare Part D formularies are governed by CMS rules. Forteo appears on many Part D formularies as a specialty tier drug. The manufacturer copay card is explicitly prohibited for Medicare beneficiaries under federal law, so cost-sharing can be substantial unless the patient qualifies for the Extra Help (Low Income Subsidy) program.

Blue Choice PPO (large employer plans). Coverage terms vary by the employer's contract with BCBSIL. Some self-funded employer plans carve out specialty pharmacy benefits entirely through a separate pharmacy benefit manager (PBM) like CVS Caremark or Express Scripts, which then applies its own formulary rather than BCBSIL's standard one. Calling the member services number on the back of your insurance card is the only reliable way to confirm coverage for these plans.

Prior Authorization: What BCBSIL Actually Requires

Prior authorization (PA) is the central hurdle for Forteo under BCBSIL. The plan's medical policy aligns closely with the American Association of Clinical Endocrinology (AACE) and the Endocrine Society guidelines on osteoporosis pharmacotherapy, both of which reserve anabolic agents for high-risk patients.

Based on publicly available BCBSIL medical policy documentation and standard industry practice, the PA criteria typically include all of the following:

1. A bone mineral density (BMD) T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, OR a documented low-trauma fracture in the setting of osteoporosis.
2. Confirmation that the prescriber is an endocrinologist, rheumatologist, or other specialist with documented experience managing osteoporosis, OR that a primary care physician has completed the required clinical documentation.
3. Evidence of an adequate trial (generally 6 to 12 months) of an oral bisphosphonate (alendronate, risedronate, or ibandronate) or an IV bisphosphonate (zoledronic acid), unless a documented contraindication or intolerance is present.
4. Absence of conditions that FDA considers contraindications: hypercalcemia, metabolic bone diseases other than osteoporosis (including hyperparathyroidism or Paget disease), prior skeletal radiation, bone metastases, or unexplained elevation of alkaline phosphatase.
5. A treatment duration request of no more than 24 months, because the FDA label and post-marketing pharmacovigilance data cap lifetime teriparatide exposure at 2 years.

The Endocrine Society's 2019 pharmacological management guidelines state: "We recommend anabolic therapy as initial treatment for patients with very high fracture risk (for example, very low T-scores, multiple prior fractures, or fractures while on antiresorptive therapy)" (Endocrine Society Clinical Practice Guideline, 2019). If a provider can document this very-high-risk profile, BCBSIL sometimes waives the bisphosphonate step-therapy requirement, but this exception is not automatic and must be argued in the PA submission.

Step Therapy and What It Means for Your Timeline

Step therapy is a prior-authorization subtype that requires patients to try a less expensive medication first. For Forteo under BCBSIL, the "first step" is almost always a bisphosphonate.

Alendronate (Fosamax generic) costs roughly $5, $15 per month at most pharmacies and is the most common step-therapy requirement. If a patient has already been on alendronate for at least 6 months without adequate response (defined as continued bone loss on DXA or a new fracture), BCBSIL will generally accept that trial as fulfilling the step-therapy requirement.

Documented intolerance works as a bypass. Bisphosphonate-related esophageal injury, severe musculoskeletal pain (a recognized adverse effect noted in the FDA label for oral bisphosphonates), atrial fibrillation concerns, or significant renal impairment (creatinine clearance <30 to 35 mL/min, which excludes most oral bisphosphonates per prescribing information) all constitute legitimate contraindications that a prescribing physician can document.

RANK-L inhibitor (denosumab/Prolia) step. Some BCBSIL formularies for commercial plans also list denosumab as an acceptable prior step before Forteo, particularly if bisphosphonates are contraindicated. Denosumab 60 mg every 6 months is a Tier 3 specialty item on most BCBSIL plans but still significantly cheaper than teriparatide.

The practical timeline: if your physician submits a PA request with complete documentation, BCBSIL is required under Illinois law (215 ILCS 5/155.22b) to issue an urgent PA decision within 72 hours and a standard PA decision within 2 business days of receiving all required information. If the initial request is denied, you have appeal rights both through BCBSIL's internal appeals process and through the Illinois Department of Insurance external review process.

How Much Will You Actually Pay?

Cost-share calculations depend on three variables: your plan's specific formulary tier for teriparatide, whether you have met your deductible, and whether you qualify for manufacturer or third-party assistance.

Without assistance, typical out-of-pocket scenarios:

A BCBSIL commercial PPO member with a 30% coinsurance Tier 4 specialty benefit and a $1,500 deductible who has not yet met the deductible in January could owe the full contracted rate (often $1,800, $2,500 per pen) for the first fill. After the deductible, at 30% coinsurance on a $2,200 contracted price, the member owes roughly $660 per month.

The Lilly Forteo Savings Card. Eli Lilly offers a savings card through its manufacturer assistance program. Eligible commercially insured patients (not on Medicare or Medicaid) may pay as little as $4 per pen fill, with a program maximum benefit of $9,000 per year. Enrollment requires confirming commercial insurance eligibility at the time of each fill. The program does not cover the full duration of treatment if costs exceed the annual cap.

Patient assistance programs. Lilly's Lilly Cares Foundation Patient Assistance Program provides Forteo at no cost to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). An application submitted by the prescriber can take 2 to 4 weeks to process.

Authorized generic teriparatide. Eli Lilly's authorized generic teriparatide (launched in 2019) carries a substantially lower list price. Some BCBSIL formularies place it on Tier 3 rather than Tier 4, and the PA criteria are typically identical to those for brand Forteo. For patients who qualify clinically, asking specifically for the authorized generic can reduce cost-share by 30 to 50% on plans that tier it lower.

Alternatives BCBSIL May Prefer Over Forteo

Insurance plans do not cover Forteo in a vacuum. Prescribers and patients navigating BCBSIL denials should know the formulary alternatives.

Abaloparatide (TYMLOS, Radius Health). TYMLOS is another anabolic PTH-related peptide approved in 2017. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg/day reduced new vertebral fracture risk by 86% versus placebo over 18 months (P<0.001), compared with 80% for teriparatide in the same trial (Eastell R et al., JAMA 2017). BCBSIL's step-therapy rules for TYMLOS are substantially similar to those for Forteo, but some plan formularies place TYMLOS on a lower specialty tier, making it the preferred anabolic agent.

Romosozumab (Evenity, UCB/Amgen). Romosozumab, a sclerostin inhibitor approved in 2019, is a once-monthly subcutaneous injection given for 12 months. The FRAME trial (N=7,180) showed romosozumab 210 mg monthly reduced new vertebral fracture by 73% at 12 months versus placebo (Cosman F et al., NEJM 2016). BCBSIL's medical policy for romosozumab generally carries the same bisphosphonate step-therapy requirement and has an additional cardiovascular risk-screening criterion (the FDA added a black box warning for myocardial infarction and stroke). For patients with no cardiovascular history, romosozumab may be easier to get approved on some employer plans than Forteo.

Denosumab (Prolia, Amgen). While not anabolic, denosumab 60 mg subcutaneously every 6 months is widely covered by BCBSIL on Tier 3 with relatively straightforward PA. The FREEDOM trial (N=7,808) showed denosumab reduced vertebral fracture risk by 68% at 36 months versus placebo (Cummings SR et al., NEJM 2009). For patients who cannot tolerate oral bisphosphonates, denosumab is often the easiest specialty osteoporosis agent to get covered under BCBSIL.

What Your Doctor Should Include in the Prior Authorization Letter

A well-crafted PA letter dramatically increases approval rates. Based on BCBSIL's published medical policy criteria, the prescribing physician should document:

• The patient's most recent DXA report with T-scores at the lumbar spine and hip, performed within the past 24 months.
• The name, dose, duration, and outcome of prior bisphosphonate therapy, or a clear clinical explanation of why bisphosphonates are contraindicated (with lab values if renal impairment is the reason, i.e., CrCl <35 mL/min).
• Any incident fractures occurring during prior therapy, with imaging report dates.
• Calculation of 10-year fracture probability using the FRAX tool if the T-score alone does not reach the -2.5 threshold (FRAX scores above 20% for major osteoporotic fracture or above 3% for hip fracture qualify as high risk per the National Osteoporosis Foundation guidelines, NOF Clinician's Guide 2014).
• Confirmation that the patient has no contraindications listed in the FDA label.
• A requested treatment duration of 24 months or fewer with a plan for subsequent antiresorptive therapy after Forteo, because abrupt discontinuation without a follow-on antiresorptive leads to rapid bone loss.

The follow-on antiresorptive plan matters clinically, not just administratively. A 2017 study published in the Journal of Bone and Mineral Research (N=1,099) found that patients who received zoledronic acid within 6 months of completing teriparatide therapy maintained significantly higher BMD gains at 24 months compared with those who received no follow-on treatment (Cosman F et al., J Bone Miner Res 2017). Including this transition plan in the PA letter signals to the BCBSIL medical reviewer that the prescriber has a complete clinical strategy, which can help tip a borderline approval.

Appealing a BCBSIL Denial for Forteo

Denials happen even with complete documentation. The appeal process has three stages under Illinois law.

Level 1 internal appeal. Submit within 60 days of the denial notice. The appeal goes to a BCBSIL medical reviewer who was not involved in the initial denial. Include the original PA documentation plus any additional clinical records, peer-reviewed literature, and a letter from the prescribing physician.

Level 2 internal appeal. If Level 1 fails, you have an additional 60 days to escalate to a BCBSIL senior medical director review.

External independent review. Under the Illinois External Review Act (215 ILCS 180/), after exhausting internal appeals, the patient can request an independent medical review through the Illinois Department of Insurance. The independent reviewer's decision is binding on BCBSIL. For expensive specialty medications with strong clinical evidence, external review succeeds in overturning denials approximately 39 to 54% of the time across payer types, according to data compiled by the Commonwealth Fund (Commonwealth Fund, 2023).

A physician advisor or specialty pharmacist experienced in osteoporosis PA can prepare the appeal documentation. Many specialty pharmacies that dispense Forteo, including Accredo and CVS Specialty, have in-house PA teams that assist with appeals at no charge.

Special Circumstances: Medicare Advantage and Glucocorticoid-Induced Osteoporosis

Medicare Advantage plans. BCBSIL's Blue Cross Medicare Advantage PPO and HMO plans follow Part D formulary rules. CMS requires that specialty tier drugs be accessible through an exception process if a lower-tier alternative is clinically inappropriate. A prescriber's "formulary exception" request citing why the authorized generic or TYMLOS is medically inferior for a specific patient can trigger reduced cost-sharing equivalent to the non-specialty tier. This process is separate from PA and worth pursuing simultaneously.

Glucocorticoid-induced osteoporosis (GIOP). Patients taking prednisone at a dose of 7.5 mg/day or more for 3 months or longer face accelerated bone loss. The American College of Rheumatology 2022 GIOP guidelines recommend anabolic therapy (teriparatide or romosozumab) as first-line for very-high-risk GIOP patients rather than bisphosphonates, citing the rapid early bone loss in this population (Buckley L et al., Arthritis Rheumatol 2022). This guideline language directly supports waiving step therapy for GIOP patients in the PA request, and BCBSIL's own medical policy acknowledges GIOP as a condition where clinical judgment may override standard step-therapy requirements.

A Practical Step-by-Step Checklist Before Your Prescription Is Submitted

Coordinating coverage before Forteo is prescribed saves weeks of back-and-forth.

1. Call the BCBSIL member services number on the back of your insurance card and ask specifically: "Is teriparatide (Forteo or authorized generic) covered on my formulary, what tier is it, and what are the PA requirements?"
2. Ask your physician's office to run a benefit verification through the specialty pharmacy (Accredo, CVS Specialty, or Walgreens Specialty) before the prescription is submitted. This takes 24 to 48 hours and surfaces the exact PA criteria for your specific plan.
3. Gather your most recent DXA report, fracture history, and bisphosphonate trial documentation before the PA is submitted.
4. Enroll in the Lilly Forteo Savings Card program at the time of the first fill if you are commercially insured and not on Medicare or Medicaid.
5. If denied, request the specific denial reason code in writing before filing the Level 1 appeal, as the denial reason dictates which additional evidence will be most persuasive.

Frequently Asked Questions